Advertisement

Uro-News

, Volume 22, Issue 4, pp 48–57 | Cite as

Individuelle und multimodale Therapie nach Stufenschema

Erektile Dysfunktion — Update 2018

  • Matthias Trottmann
Zertifizierte Fortbildung
  • 179 Downloads

Zusammenfassung

Schätzungen zufolge leiden sechs bis acht Millionen Männer in Deutschland unter einer Erektionsstörung. Auf eine individualisierte Diagnostik sollte eine Stufentherapie folgen. Multimodal umgesetzt führt diese zu einer hohen Ansprechrate.

Literatur

  1. 1.
    Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12(6):305–11.CrossRefPubMedGoogle Scholar
  2. 2.
    May M, Gralla O, Knoll N, et al. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: Results from the Cottbus Survey with 10.000 men. BJU Inter. 2007; 100(5): 1110–5.Google Scholar
  3. 3.
    European Association of Urology (EAU), Hrsg. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation [Internet]. Aarnheim/Niederlande: EAU; 2016 [zitiert am 5.2.2018]. Verfügbar unter: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Sexual-Dysfunction-2016-3.pdf
  4. 4.
    Montorsi P, Ravagnani PM, Galli, S et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005; 96(12B): 19M–23M.CrossRefPubMedGoogle Scholar
  5. 5.
    Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010; 7: 2805–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014; 127(3): 174–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Trottmann M, Becker AJ. Andrologie. In: Hegele A, Skrobek L (Hrsg.). Essentials Intensivkurs zur Weiterbildung — Urologie. 1. Aufl. Georg Thieme Verlag KG; 2015.Google Scholar
  8. 8.
    Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11(6): 319–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006; 2(4): 447–55.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry. 2003; 64 Suppl 10: 5–10.PubMedGoogle Scholar
  11. 11.
    Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013; 10(1): 130–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Reisman Y, Porst H, Lowenstein L, et al. The ESSM Manual of Sexual Medicine. 2. Auf. Amsterdam: Medix Publishers; 2015.Google Scholar
  13. 13.
    American Urology Association (AUA) [Internet]. Linthicum, MD/USA: AUA; 2011 [zitiert am 5.2.2018]. Erectile Dysfunction. Verfügbar unter: http://www.auanet.org/guidelines/erectile-dysfunction-(2005-reviewed-and-validity-confirmed-2011).
  14. 14.
    La Vignera S, Condorelli S, Vicari E, et al. Physical activity and erectile dysfunction in middle-aged men: a brief review. J Andrology 2012; 33(2): 154–61.CrossRefGoogle Scholar
  15. 15.
    Cheetham TC, Van Den Eeden SK, Jacobsen SJ. Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look to Additional Parameters. JAMA Intern Med. 2017; 177(9): 1393–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017; 72(6): 1000–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Trottmann M, Marcon J, Pompe S, et al. [Conservative therapy of erectile dysfunction]. Urologe A 2015; 54 (5): 668–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004; 45: 339–45.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009; 51(9): 650–61.CrossRefGoogle Scholar
  20. 20.
    Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev. 2017; https://doi.org/10.1016/j.sxmr.2017.08.001.Google Scholar
  21. 21.
    Vernet D, Magee T, Qian A, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006; 3(1): 84–94.CrossRefPubMedGoogle Scholar
  22. 22.
    McMurray JG, Feldman RA, Auerbach SM, et al. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007; 3(6): 975–81.PubMedPubMedCentralGoogle Scholar
  23. 23.
    McCullough AR. Four-year review of Sildenafil citrate. Rev Urol. 2002; 4: S26–38.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Romero Otero J, García Gómez B, Medina Polo J, et al. Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. Urology 2014; 83(6): 1334–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl. 2005; 28(5): 260–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Bansal UK, Jones C, Fuller TW, et al. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology 2017; https://doi.org/10.1016/j.urology.2017.08.031.Google Scholar
  27. 27.
    Osmonov DK, Jünemann KP, Bannowsky A. The „Kiel Concept“ of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation. Sex Med Rev. 2017; 5(3): 387–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol. 1998; 159: 433–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract. 1994; 48(3): 133–6.PubMedGoogle Scholar
  30. 30.
    Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. 1987; 2(8556): 421–3.CrossRefPubMedGoogle Scholar
  31. 31.
    Melnik T, Soares BGO, Nasello AG. The evectiveness of psychological interventions for the treatment of erectile dysfunction: Systematic review and meta-analysis, Including comparisons to sildenafil treatment, intracavernosal injection, and vacuum Devices. J Sex Med. 2008; 5: 2562–74.CrossRefPubMedGoogle Scholar
  32. 32.
    Hartmann U. Serie: Sexuelle Funktionsstörungen — Psychosomatische Aspekte bei Erektionsstörungen. Dtsch Arztebl. 200; 97(10): A-615/B-534/C-488.Google Scholar
  33. 33.
    Graham P, Collins JP, Thijssen AM. Popularity of the vacuum erection device in male sexual dysfunction. Int J Impot Res. 1998; 10: S6.Google Scholar
  34. 34.
    Porst H. Transurethral alprostadil with MUSE versus intracavernous alprostadil: A comparative study in 103 patients with erectile dysfunction. Int J of Impot Res. 1997; 9:187–92.CrossRefGoogle Scholar
  35. 35.
    Raina R, Pahlajani G, Agarwal A, et al. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007; 100(6): 1317–21.CrossRefPubMedGoogle Scholar
  36. 36.
    Urciuoli R, Cantisani TA, Carlini M, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004; (2): CD001784.Google Scholar
  37. 37.
    Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995; 22(4): 833–45.PubMedGoogle Scholar
  38. 38.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997; 336(1): 1–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996; 334(14): 873–7.CrossRefPubMedGoogle Scholar
  40. 40.
    McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999; 162(6): 1992–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007; 4: 1074–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Henry GD, Donatucci CF, Conners W, et al. An Outcomes Analysis of over 200 Revision Surgeries for Penile Prosthesis Implantation: A Multicenter Study. J Sex Med. 2012; 9(1): 309–15.CrossRefPubMedGoogle Scholar
  43. 43.
    Mulcahy JJ, Wilson SK. Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006; 7(6): 485–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Marcon J, Stief CG, Trottmann M. Alterantive Therapieoptionen bei erektiler Dysfunktion. URO-NEWS 2016; 20 (10): 48–53.CrossRefGoogle Scholar
  45. 45.
    Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. 2010; 58(2): 243–8.Google Scholar
  46. 46.
    Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis.. 2017; 71 (2): 223–33.Google Scholar
  47. 47.
    Fojecki GL, Tiessen S, Osther PJ, Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction-A Double-Blinded, Sham-Controlled, Randomized Clinical Trial. J Sex Med. 2017; 14 (1): 106–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Urologie Andrologie am PromenadeplatzMünchenDeutschland

Personalised recommendations